Reviva Pharmaceuticals Holdings Inc. (RVPH) continues to draw attention as a late-stage biopharmaceutical company advancing next-generation therapeutics for diseases with significant unmet medical needs.
The company's pipeline is centered on central nervous system (CNS), inflammatory, and cardiometabolic conditions, with two in-house discovered drug candidates: brilaroxazine (RP5063) and RP1208. Both compounds are protected by composition of matter patents in the United States, Europe, and several other countries.
For comments and feedback contact: editorial@rttnews.com
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.